Compounded non-FDA–approved menopausal hormone therapy prescriptions have increased-Reference-Cited by-同舟云学术

Compounded non-FDA–approved menopausal hormone therapy prescriptions have increased

Published:2016-04 Issue:4 Volume:23 Page:359-367
ISSN:1072-3714
Container-title:Menopause
language:en
Short-container-title:

Author:

Pinkerton JoAnn V.,Constantine Ginger D.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Obstetrics and Gynecology

Reference29 articles.

1. The 2012 hormone therapy position statement of: The North American Menopause Society.;Menopause,2012

2. Continuing decline in hormone therapy use: population trends over 17 years.;MacLennan;Climacteric,2009

3. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010.;Sprague;Obstet Gynecol,2012

4. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Womens Health Initiative.;Steinkellner;Menopause,2012

5. Trends inhormone replacement therapy drug utilization and expenditures for adult women in the US civilian noninstitutionalized population, 2001-2008.;Stagnitti;Agency Healthc Res Qual,2011

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. POESIT recommendations on management of body-identical hormones in menopausal symptoms;Climacteric;2024-07-03

2. Comparative estrogen exposure from compounded transdermal estradiol creams and Food and Drug Administration-approved transdermal estradiol gels and patches;Menopause;2023-10-18

3. Concerns About Compounded Bioidentical Menopausal Hormone Therapy;The Cancer Journal;2022-05

4. Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women: a systematic review and meta-analysis of randomized controlled trials;Menopause;2022-02-14

5. Concerns about safety and efficacy of compounded bioidentical hormone therapy;Menopause;2021-06-14